Team Year Parts Track Project Title
NEU-China 2016 Parts New Application ITS COLOUR: A Light-inducible CRISPR/Cas9-mediated gene expression activation system in E. Coli and Yeast
Aachen 2015 Parts Manufacturing Upcycling Methanol into a Universal Carbon Source
BGU_Israel 2015 Parts Health & Medicine The Boomerang system: engineering logic gate genetic device for detection and treatment of cancer
BostonU 2015 Parts Foundational Advance Developing conditionally dimerizable split protein systems for genetic logic and genome editing applications
Chalmers-Gothenburg 2015 Parts New Application A study in Scarlet
Hong_Kong_HKU 2015 Parts New Application Controllable cell death and DNA degradation by CRISPR cas system
NJAU_China 2015 Parts New Application The Horcrux
Paris_Bettencourt 2015 Parts Food & Nutrition Ferment It Yourself
SCU_China 2015 Parts Environment E. pangu: The Pioneer of Mars
Stanford-Brown 2015 Parts Manufacturing biOrigami: A New Approach to Reduce the Cost of Space Missions
Tec-Monterrey 2015 Parts New Application Insects join iGEM: Sf9 cells as a new chassis for synthetic biology
Tufts 2015 Parts Health & Medicine Delivery of the CRISPR-Cas9 gene editing platform into epithelial cells using Clostridium difficile toxin B
Waterloo 2015 Parts Foundational Advance CRISPieR: re-engineering CRISPR-Cas9 with functional applications in eukaryotic systems
Yale 2015 Parts Foundational Advance Developing a Framework for the Genetic Manipulation of Non-Model and Environmentally Significant Microbes
USTC 2015 Parts Hardware NDM: Nanomachine Detecting Microbiotics
Vilnius-Lithuania 2015 Parts Foundational Advance Controlling the Lifetime of GMOs using ColiClock
Duke 2015 Parts Foundational Advance DNA Sequence Sensing with dCas9 Applied to Antibiotic Resistance Detection and Elimination
EPF_Lausanne 2015 Parts Information Processing Bio LOGIC: Biologic Orthogonal gRNA-Implemented Circuit
NU_Kazakhstan 2015 Parts Health & Medicine Prevention of Dental Caries by Targeting Streptococcus Mutans
Peking 2015 Parts Health & Medicine Fighting Against Tuberculosis: Making Invisible Visible
Tsinghua 2015 Parts Hardware Developing light-controlled systems to manipulate genetic information in prokaryotes
Washington 2015 Parts New Application Lab on a Strip: Developing a Novel Platform for Yeast Biosensors
William_and_Mary 2015 Parts Measurement Measurement of Promoter-Based Transcriptional Noise for Application in Gene Network Design
British_Columbia 2013 Parts Food & Energy ~
Chiba 2013 Parts New Application ~
Duke 2013 Parts New Application ~
Freiburg 2013 Parts Foundational Advance ~
MIT 2013 Parts Health & Medicine ~
NJU_NJUT_China 2013 Parts New Application ~
Paris_Bettencourt 2013 Parts Health & Medicine ~
Penn_State 2013 Parts Manufacturing ~
SJTU-BioX-Shanghai 2013 Parts New Application ~
Stanford-Brown 2013 Parts New Application ~
UCSF 2013 Parts Foundational Advance ~
WHU-China 2013 Parts New Application ~

Introduction to CRISPR and Cas9

From UBC 2013: CRISPRs (Clustered Regularly Interspaced Short PalindromicRepeats) are specific regions in some bacterial and archaeal genomes that, together with associated Cas (CRISPR-associated) genes, function as an adaptive immune system in prokaryotes. While the specific ‘adaptive’ nature of this immunity is still under investigation, it is known that exogenous DNA is processed by Cas proteins into short (~30 base pair) sequences that are adjacent to the Protospacer Adjacent Motif (PAM) site. These short pieces of DNA are then incorporated into the host genome between repeat sequences to formspacer elements. The repeat-spacer-repeat array is constitutively expressed (pre-CRISPR RNAs or pre-crRNAs) and processed by Cas proteins to form small RNAs (crRNAs). The small RNAs are then loaded into Cas proteins and act to guide them to initiate the sequence-specific cleavage of the target sequence.

Background from Freiburg 2013: Hidden as an uncharacterized E. coli locus for more than 15 years, Barrangou et al. identified the CRISPR (Clusterd Regularly Interspaced Short Palindromic Repeats) array as a previously unknown adaptive prokaryotic immune system. Almost half of all prokaryotes make use of this defense mechanism against unselective uptake through natural transformation, phage DNA transduction or horizontal gene transfer by conjugation. Invasive DNA or even RNA can be specifically recognized and efficiently cleaved. This unique feature results from the interaction of non-coding RNAs and CRISPR associated (Cas) proteins. From a wide range of known CRISPR subtypes we used CRISPR type II b of S. pyogenes.

The recognition and degradation of invasive DNA by CRISPR/Cas type II occurs in three steps:

  1. Acquisition: Invasive DNA is recognized via a protospacer adjacent motif (PAM) – the sequence NGG. A short sequence downstream of the PAM sequence is then integrated into the host CRISPR array and is termed spacer. Spacer sequences transcribe for CRISPR RNAs(crRNAs) which help to cleave sequence-specific invasive DNA. These sequences are located between short palindromic repeats, which are neccessary for the functionality of the crRNAs.
  2. Expression/Transcription: The Cas9 endonuclease is expressed. CRISPR array is then transcribed and processed by RNAse III into crRNAs. These contain the complementary spacer sequence and the direct repeat sequence. The crRNA guides the Cas9 protein specifically to invasive DNA sequences. Furthermore trans-activating crRNAs (tracrRNA) are transcribed and bind to the direct repeat part of the crRNA. The tracrRNA is necessary for the formation of a Cas9-RNA complex.
  3. Interference: Repeatedly invading DNA, which has been integrated into the CRISPR locus, is detected by the RNA-protein complex and cleaved by Cas9.

Each of these teams have worked on CRISPR based systems for at least some part of their projects. Below, you'll find abstracts for each team, direct links to their CRISPR pages and references. Here is the list of 2013 iGEM teams who worked on CRISPR in their projects:

Team Track Chassis
British_Columbia Food & Energy E. coli
Chiba New Application E. coli
Duke New Application Yeast / S. cerevisiae
Freiburg Foundational Advance E. coli / Mammalian
MIT Health & Medicine Mammalian
NJU_NJUT_China New Application E. coli
Paris_Bettencourt Health & Medicine E. coli
Penn_State Manufacturing Plants
SJTU-BioX-Shanghai New Application E. coli
Stanford-Brown New Application E. coli / B. subtilis
UCSF Foundational Advance E. coli
WHU-China New Application E. coli

CRISPR and Cas9 parts in the Registry

Many of the teams on this page have submitted parts associated with CRISPR/Cas9:

NameDescriptionLengthCreated byDocumentationUsesType
BBa_K1218003CRISPR CasA E. coli (Modern)1509Trevor Kalkus, Gordon Wade, Alissa Greenberg1523 Coding
BBa_K1218011Cas95080Sophia Liang149242Coding
BBa_K1129006Cas 9 from Streptococcus thermophilus4167UBC iGEM 201318033 Coding
BBa_K1218004CRISPR CasA (Ancestral)1340Trevor Kalkus, Gordon Wade, Alissa Greenberg1647 Coding
BBa_K1081000J13002-dcas94180Hangxing Jia3925 Composite
BBa_K1160000coding sequence of Cas9 from CRISPR system type II9159Huang Xingxu2347 Plasmid
BBa_K1150000dCas94101Freiburg 2013736742Coding
BBa_K1150017dCas9 with CMV promoter5012Freiburg 20132996 Device
BBa_K1026000Constitutively Expressed dCas9 Operon4311Hongyi WU2561 Composite
BBa_K1026002Constitutively Expressed gRNA targeting mRFP266Hongyi WU2960 Composite
BBa_K1150050Truncated CMV dCas9 Device #43626Natalie Louis and Lisa Schmunk3242 Device
BBa_K1179002Hef1A_Cas9-VP165141Brandon Nadres10280 Generator
BBa_K1137013crRNA anti KAN251Nicolas Koutsoubelis, Anne Loechner2291 Coding
BBa_K3201000nCpf1 (RNA-guided DNA nickase)3921Anastasios Galanis 2425 Coding
BBa_K1982000tCas9-CIBN (Prokaryotic LACE system)4731Zexu Li14867 Device
BBa_K1982001Prokaryotic tCAS94122Zexu Li14274 Coding
BBa_K1982006tCas9-Vp64(Prokaryotic)4368Zexu Li4537 Device
BBa_K1982002Prokaryotic Cryptochrome 2 (CRY2) ( a blue light stimulated photoreceptor)1854Zexu Li12563 Coding
BBa_K1982003CIBN(the N-terminal fragment of CIB1)612Zexu Li13032 Coding
BBa_K1982004tCas9-CIBN (Prokaryotic LACE system)4731Zexu Li14787 Device
BBa_K1982005CRY2-VP64(Prokaryotic LACE system)2100Zexu Li13514 Device
BBa_K201701235s + TFL consense + RSIAT-Luciferase + Tnos2836Monica Victoria Gutierrez Salazar4651 Device
BBa_K1994013sgRNA with dCas9 binding site sequence 9 and PP7 handle insert189Liam Carroll2458 RNA
BBa_K1994017sgRNA with 5' golden gate adapter and PP7 protein binding site178Liam Carroll1360 RNA
BBa_K2017000C-split Cas9 + DnaE C-intein2358Monica Victoria Gutierrez Salazar8961 Protein_Domain
BBa_K2017001N-split Cas9 + DnaE N-intein2241Monica Victoria Gutierrez Salazar9032 Protein_Domain
BBa_K201700735s:5'+ Ga20ox consense + SAGTI-Luciferase + Tnos3057Monica Victoria Gutierrez Salazar6306 Device
BBa_K201700835s + Ga20ox consense + RSIAT-Luciferase + Tnos2836Monica Victoria Gutierrez Salazar6380 Device
BBa_K201700935s + Ga20ox consense + AEK-Luciferase + Tnos2872Monica Victoria Gutierrez Salazar6116 Device
BBa_K201701135s:5' + TFL consense + SAGTI-Luciferase + Tnos3057Monica Victoria Gutierrez Salazar4724 Device
BBa_K2017010 35s + Ga20ox consense + RSIAT-TEV-Luciferase + Tnos2869Monica Victoria Gutierrez Salazar4519 Device
BBa_K2017014 35s + TFL consense + RSIAT-TEV-Luciferase + Tnos2869Monica Victoria Gutierrez Salazar4670 Device
BBa_K2017013 35s + TFL consense + AEK-Luciferase + Tnos2872Monica Victoria Gutierrez Salazar4664 Device
BBa_K1982007Eukaryotic tCAS94121Zexu Li14268 Coding
BBa_K1982008tCas9-CIBN (Eukaryotic LACE system)4731Zexu Li14761 Coding
BBa_K1982010CRY2-VP64(Eukaryotic LACE system)2100Zexu Li14604 Coding
BBa_K1982011tCas9-Vp64(Eukaryoticc)4368Zexu Li4612 Coding
BBa_K1946002sgRNA targeting LacI205Musa Efe Işılak2488 RNA
BBa_K1994021sgRNA containing two golden gate adapters157Isobel Holden3455 RNA
BBa_K1994025BsaI-GFP-dCas9 5075Egheosa Ogbomo10189 Composite
BBa_K2483005sgRNA target site couples facing each other with 6 bp spacer850Sophia Borowski3307 DNA
BBa_K2483006sgRNA target site couples facing each other with 18 bp spacer955Bryan Nowack3217 DNA
BBa_K2361000spdCas94120Mart Bartelds6415 Coding
BBa_K2361001dCas9 VRER4108Mart Bartelds6255 Coding
BBa_K2361004CRISPR array639Sebald Verkuijl1474 RNA
BBa_K2371006sgRNA generator for EML4-ALK variant A 83164Qi Xiao5823 Composite
BBa_K2371005sgRNA generator for EML4-ALK variant A 33164Qi Xiao5817 Composite
BBa_K2371004sgRNA generator for EML4-ALK variant A 23164Qi Xiao5823 Composite
BBa_K2558201dCas9 generator with Anderson weak promotor4308Tianze Huang1889 Generator
BBa_K2627004crRNA targeting GltA477Zhaoqin Zhang6629 Composite
BBa_K2660006N-Cas93459Victor Nunes de Jesus, Danielle Biscaro Pedrolli3252 Coding
BBa_K2558003dCas94107Tianze Huang81546Coding
BBa_K2627003crRNA targeting GltA162Zhaoqin Zhang6678 RNA
BBa_K2660007C-Cas9648Danielle Biscaro Pedrolli,Victor Nunes de Jesus3637 Coding
BBa_K3454000MCR-1_crRNA_A_Synthesis63Mingxuan Chi -1Other
BBa_K3454001MCR-1_crRNA_B_Synthesis63Mingxuan Chi -1Other
BBa_K2483004regulated dCas9 with sgRNAs and IAA enzymes fused to MS2 and PP710136Bryan Nowack3212 Composite
BBa_K1026001dCas94113Hongyi WU27532Coding
BBa_K1137014tracRNA-CAS9 4522Nicolas Koutsoubelis, Anne L?chner4051 Coding
BBa_K1559002rearranged CRISPR/Cas9 system without promoter5080Xiuqi (Rex) Xia24816Coding
BBa_K1559003CRISPR/Cas9 system with Anderson high-expression constitutive promoter5127Xiuqi (Rex) Xia1313 Generator
BBa_K1559004CRISPR/Cas9 system with Anderson medium-expression constitutive promoter5127Xiuqi (Rex) Xia1316 Generator
BBa_K1559005CRISPR/Cas9 system with Anderson low-expression constitutive promoter5127Xiuqi (Rex) Xia1292 Generator
BBa_K1559006CRISPR/Cas9 system with pBAD inducible promoter5222Xiuqi (Rex) Xia1291 Generator
BBa_K1559007CRISPR/Cas9 system with pLac inducible promoter5147Xiuqi (Rex) Xia1291 Generator
BBa_K1559008CRISPR/Cas9 system with pRha inducible promoter5214Xiuqi (Rex) Xia1239 Generator
BBa_K1774001Cas9 (optimized for expression in E. coli)4107HKU iGEM 201515331Coding
BBa_K1994015sgRNA with 5' golden gate adapter and COM protein binding site176Liam Carroll1355 RNA
BBa_K1994016sgRNA with 5' golden gate adapter and MS2 coat protein binding site172Liam Carroll1360 RNA
BBa_K1994019Multiple dCas9 binding site sequence239Liam Carroll13372Regulatory
BBa_K1982009Eukaryotic Cryptochrome 2 (CRY2) ( a blue light stimulated photoreceptor)1848Zexu Li12797 Coding
BBa_K1994044dCas9 Promoter48Egheosa Ogbomo13133Regulatory
BBa_K1982012VP64 transcription activitor246Zexu Li10998 Protein_Domain
BBa_K2483002Lac regulated dCas9 with LacI constitutively expressed5674Bryan Nowack1929 Device
BBa_K2558006gRNA targeting PhIF promotor96Tianze Huang13853RNA
BBa_K2558007gRNA targeting lux pR and RiboJ96Tianze Huang17502RNA

British Columbia 2013

CRISPR used by UBC

Abstract: The past decade has seen the emergence of robust bioprocessing strains engineered to synthesize discrete molecular products. The next-generation of strains could be “programmable,” with on demand generation of molecules within a bioreactor e.g. a yogurt fermentation capable of making any combination of flavouring, nutrients or pharmaceuticals. While merging all this potential into single hosts seems efficient, it would also bring added risk in the case of a process failure due to bacteriophage infection. Here, we not only rationally design widespread immunity to phage infection, but also hack this immunity system to yield programmable biosynthesis at the community level. We demonstrate this by building both broadly and specifically neutralizing CRISPR systems that were paired with biosynthetic capabilities for vanillin, caffeine and cinnamaldehyde production. Eventually, a fermentative process could exist that is vaccinated to phage infection but susceptible to targeted phage addition that results in a programmable probiotic – or ultrabiotic.

Chiba 2013

CRISPRi used by the Chiba team

Abstract: In nature, there exist a variety of magnetotactic bacteria. Recently, it was reported that non-magnetotactic cells such as yeast can be magnetized to some extent. We set the goal to transform E. coli into those that are attracted by magnets. By magnetizing E. coli, the cell harvesting process will be much simpler and more economical than the conventional processes such as centrifugation and filtration. To this end, we are conducting three itemized projects. (1) modification of iron transportation network to import as much Fe ions as possible in E. coli, (2) sequestering/ storing iron into human ferritin, and (3) converting cytosolic space from reducing to oxidizing in order to elevate Fe(II)/ Fe(III) ratio within. Because all such manipulations significantly impact the physiology of the host cell, we are establishing the BioBrick platform that enables the temporal knockdown of multiple genes using recently control technology such as CRISPRi.

Duke 2013

Abstract: Synthetic gene circuits have the potential to revolutionize gene therapies and bio-industrial methods by allowing predictable, customized control of gene expression. Bistable switches and oscillators, key building blocks of more complex gene networks, have been constructed using naturally occurring and well-characterized regulatory elements. In order to expand the versatility and variety of these circuits, we designed and constructed gene networks using artificial transcription factors (ATFs). The ATFs are of two classes: inhibitory TAL proteins and a catalytically inactive dCas9 protein with small guide RNA elements, each orthogonal to the yeast genome. Using mathematical modeling, we determined the parameters expected to create bistability and oscillation, using tandem binding site kinetics to achieve cooperativity. Based on these results, we assembled a library of plasmids containing ATFs, binding sites, regulatory elements, and fluorescent reporters. We then integrated these genes into the genome of Saccharomyces cerevisiae and are currently characterizing them using flow cytometry.

CRISPR References:

  1. Qi L.S, Larson M.H, Gilbert L.A, Doudna J.A, Weissman J.S, Arkin A.P, Lim W.A: Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 2013, 152:1173-1183.
  2. DiCarlo J, Norville J, Mali P, Rios X, Aach J, Church M: Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic Acids Research 2013. 41(7), 4336-4343.

Freiburg 2013

Freiburg CRISPR page

Abstract: Our Team developed a universal toolkit, termed uniCAS, that enables customizable gene regulation in mammalian cells. Therefore, we engineered the recently discovered and highly promising CRISPR/Cas9 system. The regulation is based on the RNA-guided Cas9 protein, which allows targeting of specific DNA sequences. Our toolkit comprises not only a standardized Cas9 protein, but also different effector domains for efficient gene activation or repression. We further engineered a modular RNA plasmid for easy implementation of RNA guide sequences. As an additional feature, we established an innovative screening method for assessing the functionality of our uniCAS fusion proteins. Single genes and even whole genetic networks can be modified using our uniCAS toolkit. We think that our toolbox of standardized parts of the CRISPR/Cas9 system offers broad application in research fields such as tissue engineering, stem cell reprogramming and fundamental research.

Freiburg CRISPR References:

  1. Ishino, Y., et al. (1987). Nucleotide Sequence of the iap Gene in Escherichia coli. Journal of Bacteriology 169, 5429-5433.
  2. Barrangou, R., et al. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709-1712.
  3. Marraffini, L., and Sontheimer, E. (2008). CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science 322, 1843-1845.
  4. Jansen, R., et al. (2002). Identification of genes that are associated with DNA repeats in prokaryotes. Molecular Microbiology 43, 1565-1575.
  5. Makarova, K., et al. (2011). Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9, 467-477.
  6. Jinek, M., et al. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821.
  7. Cong, L., et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823.
  8. Mali, P., et al. (2013). RNA-guided human genome engineering via Cas9. Science 339, 823-826.
  9. Yamanaka, S., et al. (2012). Induced Pluripotent Stem Cells: Past, Present and Future. Cell Stem Cell 10, 678-684.
  10. Kaneshiro, K., et al. (2007). An integrated map of p53-binding sites and histone modification in the human ENCONDE regions. Genomics, 177-188.

MIT 2013


Abstract: Coordinating behavior across cell populations to form synthetic tissues requires spacial communication between individual cells. While there has been some success engineering single signals, sending multiple signaling elements spanning spatial scales for multicellular coordination remains a significant hurdle. Here, we describe a method for mammalian cell-cell communication utilizing engineered exosomes containing miRNA or protein signals. First, we demonstrate selectively packaging signaling miRNAs (miR-451 and miR-503) and synthetic fusion proteins (GFP, Cas9, and Cre recombinase each individually fused to the oligomerizing membrane targeting domain Acyl-TyA) into exosomes within cells engineered with sender genetic circuits. Next, we demonstrate that these miRNA and protein signals can modulate gene expression within cells engineered with receiver genetic circuits. Finally, we present preliminary cell-cell signaling results on populations of cocultured sender and receiver cells. Our method may enable multiplexed communication among populations of various cell types and the creation of sophisticated synthetic tissues.

MIT CRISPR references:

  1. Bacchus, William et al. Synthetic two-way communication between mammalian cells. Nat. Biotechnol. 30, 991–996 (2012)
  2. Lancaster, Madeline et al. Cerebral organoids model human brain development and microcephaly. Nature 501, 373–379 (2013)
  3. Barrangou, Rodolphe et al. CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes. Science 314, 1709-1712 (2007)
  4. Shen, B et al. Protein targeting to exosomes/microvesicles by plasma membrane anchors. J Biol Chem. (2011)

NJU NJUT China 2013

Abstract: Most bacteria and archaea can resist invading DNA and/or RNA elements via the clusters of regularly interspaced short palindromic repeats (CRISPRs).It is believed that the integrated CRISPR sequences have the ability to form a genetic memory which prevents the host from being infected.The memory exist as a DNA library in genome, artificially modified to set its target. The CRISPRs and Cas (CRISPR-associated) interact and form this prokaryotic adaptive immune system. Cas9, as a core of CRISPR system, can play a role of targeted-attacking gene "missiles". Therefore, we build a sort of plasmids, loading CRISPR system, to realize the "killing" of harmful genes and/or organisms.

CRISPR and Cas9 references:

  1. Zhang J, Rouillon C, Kerou M, et al. Structure and mechanism of the CMR complex for CRISPR-mediated antiviral immunity[J]. Molecular cell, 2012, 45(3): 303-313.
  2. Brouns S J J, Jore M M, Lundgren M, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes[J]. Science, 2008, 321(5891): 960-964.
  3. Díez-Villase?or C, Almendros C, García-Martínez J, et al. Diversity of CRISPR loci in Escherichia coli[J]. Microbiology, 2010, 156(5): 1351-1361.
  4. Marraffini L A, Sontheimer E J. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA[J]. science, 2008, 322(5909): 1843-1845.
  5. Shen B, Zhang J, Wu H, et al. Generation of gene-modified mice via Cas9/RNA-mediated gene targeting[J]. Cell research, 2013.
  6. Westra E R, Swarts D C, Staals R H J, et al. The CRISPRs, they are a-Changin': how prokaryotes generate adaptive immunity[J]. Annual review of genetics, 2012, 46: 311-339.
  7. Cong L, Ran F A, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems[J]. Science, 2013, 339(6121): 819-823.
  8. Karginov F V, Hannon G J. The CRISPR system: small RNA-guided defense in bacteria and archaea[J]. Molecular cell, 2010, 37(1): 7-19.
  9. Mali P, Yang L, Esvelt K M, et al. RNA-guided human genome engineering via Cas9[J]. Science, 2013, 339(6121): 823-826.
  10. Barrangou R, Horvath P. CRISPR: new horizons in phage resistance and strain identification[J]. Annual review of food science and technology, 2012, 3: 143-162.
  11. Hale C R, Majumdar S, Elmore J, et al. Essential features and rational design of CRISPR RNAs that function with the Cas RAMP module complex to cleave RNAs[J]. Molecular cell, 2012, 45(3): 292-302.
  12. Semenova E, Jore M M, Datsenko K A, et al. Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence[J]. Proceedings of the National Academy of Sciences, 2011, 108(25): 10098-10103.

Paris Bettencourt 2013

Abstract: We are testing new weapons for the global war against Mycobacterium tuberculosis (MTb), a pathogen that infects nearly 2 billion people. Our 4 synergistic projects aim to help in the prevention, diagnosis, and treatment of tuberculosis. 1) We are reproducing an essential MTb metabolic pathway in E. coli, where it can be easily and safely targeted in a drug screen. 2) We are building a phage-based biosensor to allow the rapid diagnosis specifically drug-resistant MTb strains. 3) We are constructing a mycobacteriophage to detect and counterselect drug-resistant Mtb in the environment. 4) We are programming E. coli to follow MTb into human macrophages and saturate it with bacteriolytic enzymes. We want to vanquish tuberculosis and build a TB-free world.

Penn State 2013

Penn State plan Cas9 project information

Abstract: Plants as Plants: Natural Factories provides a green approach to the manufacturing of valuable chemicals and materials. Through synthetic biology, we are able to control the expression of genes that regulate the production of desired secondary metabolites. Via the manipulation of established metabolic pathways, we hope to produce vanillin and butanol. The prospect of being able to synthetically produce a biofuel provides vast possibilities for the scope of synthetic biology and green energy. Additionally through the manipulation of the cellulose synthase genes, we hope to increase the biomass of plants by a hybrid plant cell wall. As shown through these projects, the use of plants provides various green energy possibilities. However, due to the limited use of plants within synthetic biology there are various regulation issues. Thus we have additionally worked on characterizing a range of plant promoters as well as introducing the Cas9 crisper system into plants.

SJTU BioX Shanghai 2013

SJTU-BioX-Shanghai CRISPR page

Abstract: Few researches have been done to regulate gene expression levels in genomic scale so far. This year we aim to combine two systems together in order to provide a universal and convenient tool which can be used to regulate different genomic genes simultaneously and independently in a quantitative way. Our project involves the newly developed gene regulating tool CRISPRi and three light-controlled expression systems induced by red, green, and blue light respectively. Simply by changing the regulating parts in CRISPRi system towards mRFP, luciferase, and three enzymes, we hope to prove our system can be used qualitatively, quantitatively and practically step by step. We have also designed a box and written a software as our experiment measurements. Simply by typing in several parameters, different gene expression levels can be controlled. This system can also be improved to predict the maximized producing efficiency after some simple tests in future.

SJTU-BioX-Shanghai CRISPR references:

  1. QI, LEI S., LARSON, MATTHEW H., GILBERT, LUKE A., DOUDNA, JENNIFER A., WEISSMAN, JONATHAN S., ARKIN, ADAM P. & LIM, WENDELL A. 2013. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. Cell, 152, 1173-1183
  2. LEVSKAYA, A., CHEVALIER, A. A., TABOR, J. J., SIMPSON, Z. B., LAVERY, L. A., LEVY, M., DAVIDSON, E. A., SCOURAS, A., ELLINGTON, A. D., MARCOTTE, E. M. & VOIGT, C. A. 2005. Synthetic biology: engineering Escherichia coli to see light. Nature, 438, 441-2.
  3. FU, Y., FODEN, J. A., KHAYTER, C., MAEDER, M. L., REYON, D., JOUNG, J. K. & SANDER, J. D. 2013. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotechnology, 31, 822-826.
  4. CARROLL, D. 2013. Staying on target with CRISPR-Cas. Nature Biotechnology, 31, 807-809.

Stanford Brown 2013

Stanford-Brown CRISPR page

Abstract: Communication is a dynamic requirement for life as we know it. We are using cellular and molecular messaging of different magnitudes to improve the broadcasting and reception of information. Starting on the atomic level, our BioWires project has created silver-incorporating DNA to act as nanowires, which could improve the cost and effectiveness of electronic products. Our CRISPR project is creating a system for DNA messages and resistances to be passed from cell to cell, in effect, creating transmissible probiotics and changing the way that cells communicate. We are also building a chromogenic biosensor to detect sucrose secretion that will be launched on a satellite (EuCROPIS) into low-Earth orbit. Finally, our De-Extinction project involves decoding messages from the past to better understand early life on Earth.

Stanford-Brown CRISPR references:

  1. Bikard, D., Jiang, W., Samai, P., Hochschild, A., Zhang, F., & Marraffini, L. A. (2013). Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Research.
  2. Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., ... & Charpentier, E. (2011). CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature, 471(7340), 602-607.
  3. Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. A. (2013). RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nature biotechnology, 31(3), 233-239.
  4. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816-821.
  5. Liu, H., & Naismith, J. H. (2008). An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. BMC biotechnology, 8(1), 91.
  6. Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., ... & Church, G. M. (2013). RNA-guided human genome engineering via Cas9. Science, 339(6121), 823-826.
  7. Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell, 152(5), 1173-1183.
  8. Quan, J., & Tian, J. (2009). Circular polymerase extension cloning of complex gene libraries and pathways. PloS one, 4(7), e6441.
  9. Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell.

UCSF 2013


Abstract: In microbial communities, bacterial populations are commonly controlled using indiscriminate, broad range antibiotics. There are few ways to target specific strains effectively without disrupting the entire microbiome and local environment. The goal of our project is to take advantage of a natural horizontal gene transfer mechanism in bacteria to precisely affect gene expression in selected strains. We combine bacterial conjugation with CRISPRi, an RNAi-like repression system developed from bacteria, to regulate gene expression in targeted strains within a complex microbial community. One possible application is to selectively repress pathogenic genes in a microbiome, leaving the community makeup unaffected. In addition, we use CRISPRi to lay the groundwork for transferring large circuits that enable complex functionality and decision-making in cells.

WHU China 2013

WHU-China CRISPR page

Abstract: Cas9 is an RNA-guided dsDNA nuclease utilized by bacteria immune system. The genetically engineered Cas9 has recently been shown to have the ability to repress or activate desired gene expression. In practical research and industrial application, we usually face the problem to express a gene at different levels, not only “on” or “off ”, so a more flexible regulation method is needed. To achieve multi-stage regulation of target genes, we further develop several dCas9 devices in which dCas9 alone or fused with omega subunit of RNAP is directed by various guide RNAs to different regions of designed double promoters. Therefore, promoters with disparate strength can be either activated or repressed respectively and multi-stage gene expression can be achieved. Also, based on such novel technology platform, we are developing diverse applications such as a guide RNA-mediated oscillator.

WHU-China CRISPR references:

  1. Qi, L.S., et al., Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell, 2013. 152(5): p. 1173-83.
  2. Jinek, M., et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012. 337(6096): p. 816-21.
  3. Bikard, D., et al., Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res, 2013. 41(15): p. 7429-7437.
  4. Heidrich, N. and J. Vogel, CRISPRs extending their reach: prokaryotic RNAi protein Cas9 recruited for gene regulation. EMBO J, 2013. 32(13): p. 1802-4.
  5. Li, M., et al., A strategy of gene overexpression based on tandem repetitive promoters in Escherichia coli. Microb Cell Fact, 2012. 11: p. 19.